PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while Healthcare median is -0.48%. Seth Klarman would investigate if market share loss is temporary.
8.54%
Cost increase while Healthcare shows cost reduction. Peter Lynch would examine competitive disadvantages.
-83.05%
Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
R&D reduction while Healthcare median is -0.61%. Seth Klarman would investigate competitive implications.
28.45%
G&A change of 28.45% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while Healthcare median is -0.82%. Seth Klarman would investigate advantages.
-7.93%
Total costs reduction while Healthcare median is -1.89%. Seth Klarman would investigate advantages.
-100.00%
Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
8.54%
D&A change of 8.54% versus flat Healthcare D&A. Walter Schloss would verify adequacy.
7.52%
EBITDA growth 1.25-1.5x Healthcare median of 5.14%. Mohnish Pabrai would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth exceeding 1.5x Healthcare median of 3.75%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
7.01%
Pre-tax income growth near Healthcare median of 7.01%. Charlie Munger would verify industry dynamics.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
7.01%
Net income growth 1.25-1.5x Healthcare median of 5.10%. Mohnish Pabrai would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth near Healthcare median of 9.26%. Charlie Munger would verify industry dynamics.
8.82%
Diluted EPS growth near Healthcare median of 9.09%. Charlie Munger would verify industry dynamics.
0.91%
Share count reduction below 50% of Healthcare median of 0.23%. Jim Chanos would check for issues.
0.91%
Diluted share reduction below 50% of Healthcare median of 0.29%. Jim Chanos would check for issues.